79.45 -0.32 (-0.40%)
Pre-Market: 8:34AM EDT
|Bid||79.30 x 2200|
|Ask||79.93 x 1300|
|Day's Range||78.57 - 80.15|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||22.29|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||112.98|
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.
This month, Celgene (CELG) presented the results of its phase 3 OPTIMISMM trial, which evaluated the safety and efficacy of Pomalyst, bortezomib (Velcade), and dexamethasone combination therapy for the treatment of individuals with relapsed or refractory multiple myeloma (or RRMM) who received at least one previous treatment. The OPTIMISIMM trial is the only phase three trial that presented results with the Pomalyst triple regimen in patients who previously underwent treatment with Revlimid.
In June 2018, Celgene (CELG) and Bluebird Bio (BLUE) presented updated results from the ongoing phase 1 CRB-401 trial of bb2121. Celgene and Bluebird’s bb2121 is an investigational anti-BCMA (anti-B-cell maturation antigen) CAR T therapy.
In June 2018, Celgene (CELG) presented the results of the phase 3 RELEVANCE trial, which it conducted in partnership with the Lymphoma Academic Research Organization (or LYSARC). The RELEVANCE trial evaluated the safety and efficacy of Revlimid and rituximab combination therapy followed by rituximab maintenance therapy in treatment-naïve patients with follicular lymphoma compared to rituximab and chemotherapy combination (or R-chemo) followed by rituximab maintenance therapy.
Celgene (CELG) reported revenues of $3.5 billion in Q1 2018, which reflected ~20% year-over-year (or YoY) growth and 1% growth sequentially. In Q1 2018, Celgene’s adjusted diluted EPS (earnings per share) rose ~23% YoY to reach $2.05. In Q1 2018, Celgene reported a gross product margin and an operating margin of 96.4% and 57.9%, respectively.
Celgene Corporation (CELG) today announced the appointment of Jonathan Biller as Executive Vice President and General Counsel effective July 3, 2018. Mr. Biller will be responsible for global legal strategy and will serve on the company's Executive Committee. Mr. Biller will succeed Gerald F. Masoudi, Celgene's Executive Vice President and General Counsel since 2015.
On Monday morning, investors came out strong and bought the trade-war dip. On Tuesday, it took more convincing, but bulls reluctantly bid U.S. equities off their lows. I don’t know how much longer they can handle it though and if trade talks intensify, U.S. stocks look likely to head lower. That’s why on days like this, I like to look for strength, which you’ll see in our top stock trades below.Top Stock Trades for Tomorrow No. 1: Netflix (NFLX)
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a medical technology company with a white-hot stock.
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Equinix, ...
Celgene has admitted it bungled an attempt to win regulatory approval for an important new drug in a “self-inflicted” error that damaged the biotech company’s credibility on Wall Street. Shares in New Jersey-based Celgene have fallen by about 22 per cent since February, when it first revealed the FDA had sent it a “refusal to file” (RTF) letter, while its market value of $56bn is roughly half its peak in autumn of last year. Shareholders fear the Ozanimod delay and other strategic mis-steps will make it harder for the company to cope with the loss of patent protection on its top medicine.
The Zacks Analyst Blog Highlights: Disney, Caterpillar, MetLife, Celgene and Northrop Grumman
The hire could fuel rumors that Alder is searching for a buyer at the same time the Bothell-based company is seeking Food and Drug Administration approval for its flagship migraine drug, eptinezumab.
No one expected Lisa McCormick to win New Jersey’s Democratic U.S. Senate primary over incumbent Bob Menendez. McCormick, publisher of a weekly newspaper and community news website in Rahway, was an underfunded political unknown yet managed to draw 38 percent of the vote Tuesday in a contest against a heavily favored, party-backed candidate. The narrower-than-expected margin of Menendez’s win suggests that some Democratic voters aren’t happy with the senator, whose federal corruption case was dropped by prosecutors after a mistrial in November.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.